Form S-3/A Galena Biopharma, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Roth Cap Remains Positive on Galena Biopharma (GALE) Following Q3 Results, Update
November 4, 2014 11:56 AM ESTRoth Capital affirms Galena Biopharma (Nasdaq: GALE) at Buy with a price target of $8 following Q3 results.
Analyst Joseph Pantginis noted that Galena's loss of $0.05 per share compared with the firm's loss estimate of $0.18 per share and the consensus loss of $0.11 per share. The analyst noted that, Revenue, based on Abstral sales came in at $1.62 million compared with our estimate of $2.34 million and the consensus estimate of $2.66 million and the company reiterated... More
Galena Biopharma (GALE) Tops Q3 EPS by 6c
November 3, 2014 4:21 PM ESTGalena Biopharma (NASDAQ: GALE) reported Q3 EPS of ($0.05), $0.06 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $2.66 million.
For earnings history and earnings-related data on Galena Biopharma (GALE) click here.
... More